Mechanistically, we found that SERPINA3 may influence the expression of CXCL2 to activate the IL-17 and TNFα signaling pathways, thereby mediating the recruitment of M1 macrophages in the tumor microenvironment and exerting an inhibitory effect on prostate cancer progression. Here, CXCL2 is linked to prostate carcinoma.